Scopus h-index:56
- Home
- Profiles
Video Visit Available
Accepting New Patients
Mount Sinai Doctors
Video Visit Available
Accepting New PatientsJohn E Levine, MD
Hematology-Oncology, Pediatric Hematology-Oncology
No Patient Experience Ratings
Ruttenberg Treatment Center
212-241-6021
- About Me
- Clinical Focus
- Education & Certifications
- Awards
- Research
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
My clinical practice focuses exclusively on patients (both adult and pediatric) who undergo Bone Marrow Transplant (BMT) and overlaps with my clinical research. I have designed, conducted, analyzed, and authored multiple clinical trials and data analyses of clinical GVHD, specifically, and clinical BMT, broadly. My long term goal is to improve outcomes for patients who undergo BMT by designing and conducting high impact clinical trials.
I co-direct the Mount Sinai Acute GVHD International Consortium [MAGIC] with James Ferrara, MD. This international consortium provides the opportunity to develop and test innovative treatment approaches for allogeneic BMT patients.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Clinical Focus
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Hematologic Malignancies
- Hematologic Malignancies, Pediatric
Education
MD, Eastern Virginia Medical School
Residency, Pediatrics
Childrens Hospital of Los Angeles
Fellowship, Pediatric Hematology/Oncology
Memorial Sloan-Kettering Cancer Center
Awards
2013
Chair, Pediatric Scientific Interest Group, ASBMT Annual Meeting
2012
Chair, Scientific Program, ASBMT Annual Meeting
2007
Best Doctors in America
2005
Ford Motor Company Leadership in Health Award
Research
My research focuses on clinical bone marrow transplantation. My primary research focus concentrates on clinical and translational studies for the diagnosis, prevention, and treatment of acute graft-versus-host disease (GVHD). In collaboration with the laboratory of James Ferrara, we developed and validated a GVHD plasma biomarker based scoring system that assigns patients to GVHD risk strata and can be used to determine treatment intensity.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:135
Review Article:24
Comment/Debate:3
Letter:4
Editorial:3
Chapter:5
Recent Artifacts
- Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study
- Effective treatment of low-risk acute GVHD with itacitinib monotherapy
- Acute GVHD: New approaches to clinical trial monitoring
- Decoupling blood telomere length from age in recipients of allogeneic hematopoietic cell transplant in the BMT-CTN 1202
- Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force
- Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients
- Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019
- Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
- Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031
- Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children’s Oncology Group experience
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Levine during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Equillium
- Symbio Pharmaceuticals
- Kamada
- Brennan Burtker
- Incyte Corporation
- Bluebird Bio
- Talaris
- Mallinckrodt
- Editas
- Novartis
- Jazz
- Falk, Waas
- Mesoblast Ltd.
- X4 Pharmaceuticals
Royalty Payments:
- ViraCor-IBT
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.